Literature DB >> 21679352

Prevalence of sleep apnoea in diabetic patients.

Anne-Katrin Schober1, Markus Friedrich Neurath, Igor Alexander Harsch.   

Abstract

BACKGROUND: Diabetes and obstructive sleep apnoea (OSA) syndrome share a high prevalence in industrialized nations. The presence of OSA seems to promote the development of diabetes mellitus (DM) and vice versa.
MATERIALS AND METHODS: In order to assess the prevalence of sleep disordered breathing, we studied 498 patients with DM type 2 and 58 patients with DM type 1 from 15 centres, using a screening device determining airflow and pulse oximetry. Age of the patients was 59.9 ± 13.1 years, mean body mass index was 31.9 ± 6.9 kg/m(2) . Duration of diagnosis of DM was 9.3 ± 7.3 years.
RESULTS: Among the patients, 37.4% had an apnoea-hypopnoea index (AHI) ≥15/h suggestive of OSA. The prevalence of an AHI ≥ 15/h among the patients with DM type 1 was 10.3%. One hundred ninety-three (35.2%) patients suffered from neuropathy. We found a higher prevalence for neuropathy, nephropathy, hypertension, cardiovascular disease and heart failure in the group with an AHI ≥ 15/h.
CONCLUSIONS: The prevalence of sleep disordered breathing is increased in patients with DM. Most of these patients had no typical clinical symptoms of OSA and would have been undiagnosed without diagnostic assessment of OSA.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21679352     DOI: 10.1111/j.1752-699X.2010.00216.x

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  45 in total

1.  Sleep, sleep apnea, diabetes, and the metabolic syndrome: the role of treatment.

Authors:  Tamar Etzioni; Giora Pillar
Journal:  Sleep       Date:  2012-05-01       Impact factor: 5.849

Review 2.  Obstructive Sleep Apnoea and Type 2 Diabetes.

Authors:  Abd A Tahrani; Asad Ali
Journal:  Eur Endocrinol       Date:  2014-02-28

3.  Subjective sleep disturbances and glycemic control in adults with long-standing type 1 diabetes: The Pittsburgh's Epidemiology of Diabetes Complications study.

Authors:  Hristina Denic-Roberts; Tina Costacou; Trevor J Orchard
Journal:  Diabetes Res Clin Pract       Date:  2016-06-18       Impact factor: 5.602

4.  Chronic intermittent hypoxia exposure induces kidney injury in growing rats.

Authors:  Neha-Devi Poonit; Yi-Chun Zhang; Chu-Yuan Ye; Hui-Lin Cai; Chen-Yi Yu; Ting Li; Xiao-Hong Cai
Journal:  Sleep Breath       Date:  2017-11-09       Impact factor: 2.816

Review 5.  Links between lower urinary tract symptoms, intermittent hypoxia and diabetes: Causes or cures?

Authors:  Lisa L Abler; Chad M Vezina
Journal:  Respir Physiol Neurobiol       Date:  2017-09-18       Impact factor: 1.931

Review 6.  Epidemiological and pathophysiological evidence supporting links between obstructive sleep apnoea and Type 2 diabetes mellitus.

Authors:  Chuen Peng Lee; Clete A Kushida; John Arputhan Abisheganaden
Journal:  Singapore Med J       Date:  2019-02       Impact factor: 1.858

Review 7.  Impact of Obstructive Sleep Apnoea on Type 2 Diabetes and Vice Versa.

Authors:  Kurt Rasche; Tanja Keller; Claus Hader; Markus Leidag; Christian Prinz
Journal:  Eur Endocrinol       Date:  2013-08-23

8.  CPAP therapy for patients with sleep apnea and type 2 diabetes mellitus improves control of blood pressure.

Authors:  Jamie Chung Mei Lam; Agnes Yuen Kwan Lai; Terence Chi Chun Tam; Michele Mae Ann Yuen; Karen Siu Ling Lam; Mary Sau Man Ip
Journal:  Sleep Breath       Date:  2016-11-05       Impact factor: 2.816

9.  Predicting Nondiagnostic Home Sleep Apnea Tests Using Machine Learning.

Authors:  Robert Stretch; Armand Ryden; Constance H Fung; Joanne Martires; Stephen Liu; Vidhya Balasubramanian; Babak Saedi; Dennis Hwang; Jennifer L Martin; Nicolás Della Penna; Michelle R Zeidler
Journal:  J Clin Sleep Med       Date:  2019-11-15       Impact factor: 4.062

Review 10.  Metabolic consequences of sleep and circadian disorders.

Authors:  Christopher M Depner; Ellen R Stothard; Kenneth P Wright
Journal:  Curr Diab Rep       Date:  2014-07       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.